Your browser doesn't support javascript.
loading
Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma.
Perrot, Aurore; Lauwers-Cances, Valerie; Corre, Jill; Robillard, Nelly; Hulin, Cyrille; Chretien, Marie-Lorraine; Dejoie, Thomas; Maheo, Sabrina; Stoppa, Anne-Marie; Pegourie, Brigitte; Karlin, Lionel; Garderet, Laurent; Arnulf, Bertrand; Doyen, Chantal; Meuleman, Nathalie; Royer, Bruno; Eveillard, Jean-Richard; Benboubker, Lotfi; Dib, Mamoun; Decaux, Olivier; Jaccard, Arnaud; Belhadj, Karim; Brechignac, Sabine; Kolb, Brigitte; Fohrer, Cecile; Mohty, Mohamad; Macro, Margaret; Richardson, Paul G; Carlton, Victoria; Moorhead, Martin; Willis, Tom; Faham, Malek; Anderson, Kenneth C; Harousseau, Jean-Luc; Leleu, Xavier; Facon, Thierry; Moreau, Philippe; Attal, Michel; Avet-Loiseau, Hervé; Munshi, Nikhil.
Affiliation
  • Perrot A; Hematology Department, University Hospital, Nancy, France.
  • Lauwers-Cances V; Epidemiology and Statistics Department, University Hospital, Toulouse, France.
  • Corre J; Myeloma Genomics Lab University Cancer Institute Toulouse (IUCT)-Oncopole, Cancer Research Center of Toulouse (CRCT), INSERM 1037, Toulouse, France.
  • Robillard N; Université Paul Sabatier, Toulouse, France.
  • Hulin C; Hematology Laboratory, University Hospital, Nantes, France.
  • Chretien ML; Hematology Department, University Hospital, Bordeaux, France.
  • Dejoie T; Hematology Department, University Hospital, Dijon, France.
  • Maheo S; Biochemistry Laboratory, University Hospital, Nantes, France.
  • Stoppa AM; Myeloma Genomics Lab University Cancer Institute Toulouse (IUCT)-Oncopole, Cancer Research Center of Toulouse (CRCT), INSERM 1037, Toulouse, France.
  • Pegourie B; Université Paul Sabatier, Toulouse, France.
  • Karlin L; Hematology Department, Institut Paoli Calmettes, Marseille, France.
  • Garderet L; Hematology Department, University Hospital, Grenoble, France.
  • Arnulf B; Hematology Department, University Hospital, Lyon, France.
  • Doyen C; Hematology Department, Saint-Antoine University Hospital, Paris, France.
  • Meuleman N; Hematology Department, Saint-Louis University Hospital, Paris, France.
  • Royer B; Hematology Department, Centre Hospitalier Universitaire (CHU) Université Catholique de Louvain (UCL) Namur, Yvoir, Belgium.
  • Eveillard JR; Hematology Department, Institut Jules Bordet (ULB), Brussels, Belgium.
  • Benboubker L; Hematology Department, University Hospital, Amiens, France.
  • Dib M; Hematology Department, University Hospital, Brest, France.
  • Decaux O; Hematology Department, University Hospital, Tours, France.
  • Jaccard A; Hematology Department, University Hospital, Angers, France.
  • Belhadj K; Hematology Department, University Hospital, Rennes, France.
  • Brechignac S; Hematology Department, University Hospital, Limoges, France.
  • Kolb B; Hematology Department, University Hospital, Creteil, France.
  • Fohrer C; Hematology Department, University Hospital, Bobigny, France.
  • Mohty M; Hematology Department, University Hospital, Reims, France.
  • Macro M; Hematology Department, University Hospital, Strasbourg, France.
  • Richardson PG; Hematology Department, Saint-Antoine University Hospital, Paris, France.
  • Carlton V; Hematology Department, University Hospital, Caen, France.
  • Moorhead M; Hematology Department, Dana-Farber Cancer Institute, Boston, MA.
  • Willis T; Adaptive Biotechnologies, Seattle, WA.
  • Faham M; Adaptive Biotechnologies, Seattle, WA.
  • Anderson KC; Adaptive Biotechnologies, Seattle, WA.
  • Harousseau JL; Adaptive Biotechnologies, Seattle, WA.
  • Leleu X; Hematology Department, Dana-Farber Cancer Institute, Boston, MA.
  • Facon T; Hematology Department, Clinique du Confluent, Nantes, France.
  • Moreau P; Hematology Department, University Hospital, Poitiers, France.
  • Attal M; Hematology Department, University Hospital, Lille, France.
  • Avet-Loiseau H; Hematology Department, University Hospital, Nantes, France; and.
  • Munshi N; Hematology Department, University Hospital, Toulouse, France.
Blood ; 132(23): 2456-2464, 2018 12 06.
Article in En | MEDLINE | ID: mdl-30249784
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Antineoplastic Combined Chemotherapy Protocols / High-Throughput Nucleotide Sequencing / Multiple Myeloma Type of study: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Blood Year: 2018 Type: Article Affiliation country: France
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Antineoplastic Combined Chemotherapy Protocols / High-Throughput Nucleotide Sequencing / Multiple Myeloma Type of study: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Blood Year: 2018 Type: Article Affiliation country: France